-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Holistic Financial Partners Acquires 1,801 Shares of AstraZeneca PLC (NASDAQ:AZN)
Holistic Financial Partners Acquires 1,801 Shares of AstraZeneca PLC (NASDAQ:AZN)
Holistic Financial Partners lifted its holdings in AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 44.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,813 shares of the company's stock after acquiring an additional 1,801 shares during the period. Holistic Financial Partners' holdings in AstraZeneca were worth $319,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Better Money Decisions LLC acquired a new position in shares of AstraZeneca during the second quarter worth $25,000. Parkside Financial Bank & Trust boosted its holdings in shares of AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company's stock valued at $26,000 after buying an additional 390 shares during the period. Fairfield Bush & CO. bought a new stake in shares of AstraZeneca during the 1st quarter worth about $28,000. HHM Wealth Advisors LLC purchased a new position in shares of AstraZeneca in the second quarter worth approximately $28,000. Finally, Hazlett Burt & Watson Inc. grew its position in AstraZeneca by 129.5% in the third quarter. Hazlett Burt & Watson Inc. now owns 514 shares of the company's stock worth $28,000 after acquiring an additional 290 shares in the last quarter. 16.42% of the stock is currently owned by hedge funds and other institutional investors.
Get AstraZeneca alerts:Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the stock. StockNews.com started coverage on shares of AstraZeneca in a report on Wednesday, October 12th. They set a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on AstraZeneca from £120 ($144.25) to £130 ($156.27) in a research report on Thursday, December 15th. JPMorgan Chase & Co. boosted their price target on AstraZeneca from £125 ($150.26) to £135 ($162.28) in a research note on Tuesday, January 3rd. Berenberg Bank upped their price objective on AstraZeneca from GBX 118 ($1.42) to GBX 126 ($1.51) in a research note on Wednesday, January 18th. Finally, BMO Capital Markets initiated coverage on AstraZeneca in a report on Thursday, January 5th. They set an "outperform" rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, AstraZeneca presently has a consensus rating of "Hold" and a consensus target price of $9,510.67.
AstraZeneca Price Performance
Shares of AZN traded down $0.18 during trading hours on Tuesday, hitting $63.34. The stock had a trading volume of 1,076,217 shares, compared to its average volume of 5,957,608. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.81 and a quick ratio of 0.61. AstraZeneca PLC has a 52 week low of $52.65 and a 52 week high of $72.12. The stock has a market capitalization of $196.33 billion, a PE ratio of 94.81, a price-to-earnings-growth ratio of 1.17 and a beta of 0.51. The company's fifty day moving average price is $68.23.AstraZeneca (NASDAQ:AZN – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $0.84 EPS for the quarter, beating analysts' consensus estimates of $0.77 by $0.07. The business had revenue of $10.98 billion during the quarter, compared to the consensus estimate of $10.98 billion. AstraZeneca had a return on equity of 29.40% and a net margin of 4.52%. Equities analysts predict that AstraZeneca PLC will post 3.33 EPS for the current fiscal year.
About AstraZeneca
(Get Rating)
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Should Investors Buy or Sell the Vaccinex Patent News?
- Take-Two Interactive Or Activision Blizzard: An Obvious Choice?
- What is a Penny Stock? What You Need to Know About Penny Stocks
- ServiceNow CEO Sells Shares, Is It Time To Worry?
- Patient Clorox Shareholders Are Cleaning Up
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
根據整體金融合夥公司最近向美國證券交易委員會披露的資訊,該公司在第三季度增持了阿斯利康(納斯達克代碼:AZN-GET評級)44.9%。在此期間,該公司額外收購了1,801股,擁有5813股該公司的股票。在最近一個報告期結束時,整體金融夥伴在阿斯利康持有的股份價值31.9萬美元。
其他對沖基金和其他機構投資者也增持或減持了該公司的股份。Better Money Decitions LLC在第二季度收購了價值2.5萬美元的阿斯利康股票的新頭寸。Parkside Financial Bank&Trust在第一季度增持了4875.0%的阿斯利康股票。Parkside Financial Bank&Trust現在擁有該公司398股股票,價值2.6萬美元,在此期間又購買了390股。費爾菲爾德·布什公司在第一季度購買了價值約2.8萬美元的阿斯利康新股。HHM Wealth Advisors LLC在第二季度購買了價值約28,000美元的阿斯利康新股頭寸。最後,黑茲利特·伯特·沃森公司在第三季度將其在阿斯利康的持倉增加了129.5%。黑茲利特·伯特·沃森公司在上個季度增持了290股股票後,現在持有514股該公司股票,價值28,000美元。16.42%的股票目前由對沖基金和其他機構投資者持有。
到達阿斯利康警報:分析師升級和下調評級
許多股票研究分析師對該股發表了評論。StockNews.com在10月12日星期三的一份報告中開始報道阿斯利康的股票。他們對該股設定了“買入”評級。德意志銀行Aktiengesellschaft週四在一份研究報告中將阿斯利康的目標價從120 GB(144.25美元)上調至130 GB(156.27美元)。摩根大通在1月3日週二的一份研究報告中將阿斯利康的目標價從125 GB(150.26美元)上調至135 GB(162.28美元)。貝倫貝格銀行在1月18日星期三的一份研究報告中將阿斯利康的目標價從118英鎊(1.42美元)上調至126英鎊(1.51美元)。最後,蒙特利爾銀行資本市場在1月5日星期四的一份報告中開始了對阿斯利康的報道。他們為該股設定了“跑贏大盤”的評級。一名分析師對該股的評級為賣出,五名分析師給出了持有評級,六名分析師給出了該公司的買入評級。根據MarketBeat的數據,阿斯利康目前的共識評級為持有,共識目標價為9,510.67美元。
阿斯利康的性價比
週二交易時段,AZN股價下跌0.18美元,觸及63.34美元。該股成交量為1,076,217股,而其平均成交量為5,957,608股。該公司的債務權益比為0.65,流動比率為0.81,速動比率為0.61。阿斯利康的52周低點為52.65美元,52周高點為72.12美元。該股市值為1,963.3億美元,本益比為94.81,本益比為1.17,貝塔係數為0.51。該公司的50日移動均線價格為68.23美元。阿斯利康(納斯達克代碼:AZN-GET Rating)最近一次公佈季度收益是在11月10日星期四。該公司公佈本季度每股收益為0.84美元,比分析師普遍預期的0.77美元高出0.07美元。該業務本季度營收為109.8億美元,而市場普遍預期為109.8億美元。阿斯利康的股本回報率為29.40%,淨利潤率為4.52%。股票分析師預測,阿斯利康本財年每股收益將達到3.33%。
關於阿斯利康
(獲取評級)
阿斯利康是一家從事醫藥產品研究、開發和製造的控股公司。它專注於腫瘤學和生物製藥領域處方藥的發現、開發和商業化,包括心血管、腎臟和新陳代謝以及呼吸和免疫學。
閱讀更多內容
- 免費獲取StockNews.com關於阿斯利康(AstraZeneca)的研究報告
- 投資者應該買入還是賣出Vaccinex專利新聞?
- Take-Two互動版還是動視暴雪:顯而易見的選擇?
- 什麼是便士股票?你需要知道的關於細價股的事情
- ServiceNow CEO拋售股票,是時候擔心了嗎?
- 耐心的高樂氏股東正在清理
接受阿斯利康日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對阿斯利康和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧